Nurix Therapeutics, Inc. Common stock

NRIX XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

1.7B

Short interest (May 15)

18.0%

Net Short (Jun 03 ): -0.1%

Borrow Fee

0.35%

↓ 3.3%

Available Shares

↑ 55.9%

Price Chart

Company Overview

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001549595

Asset Type: CS

Market Data

Market Cap: $1,692,753,158

Employees: 357

Status: Active

Short Interest

Current Borrow Fee 0.35%

Range: 0.35% - 0.40%

Available Shares 1M

Range: 1.1M - 1.2M

Recent Changes

Fee Change: ↓ 6.4%

Available Change: ↓ 14.3%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime